SMAD4 and head and neck squamous cell carcinoma: In a subsequent analysis of tissue microarrays for SMAD4 expression, Martin et al. found detectable SMAD4 expression in ~ 82% of HNSCC patients by immunohistochemistry, suggesting that a substantial patient population could potentially benefit from a TGF-ß receptor inhibitor therapy.